

Randomised trial of treatment of chronic suppurative otitis media (CSOM) in Kenyan children

Submission date 25/11/2008	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 17/12/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 16/05/2022	Condition category Ear, Nose and Throat	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ian Mackenzie

Contact details
Liverpool School of Tropical Medicine
Liverpool
United Kingdom
L3 5QA
+44 (0)151 705 3144
macken34@liv.ac.uk

Additional identifiers

Study information

Scientific Title
Treatment of chronic suppurative otitis media (CSOM) in Kenyan children: a double blind, two-group comparative randomised placebo controlled trial

Acronym
COMIGS

Study objectives

The addition of oral zinc sulphate supplements (20 mg elemental zinc/day) to current best treatment (aural antibiotics instilled after ear cleaning) is more effective than current best treatment alone in time to resolution of chronic suppurative otitis media (CSOM) in children.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Pending as of 25/11/2008:

1. University of Nairobi Ethics Committee: submitted 18/11/2008
2. Liverpool School of Tropical Medicine Ethics Committee: submitted 20/11/2008

Study design

Double blind, two-group comparative randomised placebo controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic suppurative otitis media (CSOM)

Interventions

1. Six weeks of weekly oral zinc sulphate supplement (20 mg) together with 10 days of aural ciprofloxacin 0.3% ear drops
2. Six weeks of weekly oral placebo together with 10 days of aural ciprofloxacin 0.3% ear drops

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Zinc sulphate supplement, ciprofloxacin

Primary outcome(s)

Healing of the tympanic membrane at 42 days with no evidence of perforation on otoscopy, tympanometry or the Rinne Test has changed from negative to positive.

Key secondary outcome(s)

1. Resolution of aural discharge
2. Any change of 10 decibels or more over the speech frequencies
3. Safety profiles of the two treatments

Children will be reviewed at 6, 10 and 16 weeks.

Completion date

01/02/2010

Eligibility

Key inclusion criteria

1. Aged 5 years or older, either sex
2. Presence of purulent aural discharge for 14 days or longer
3. Presence of pus in the external ear canal on otoscopy
4. Perforation of the tympanic membrane

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

5 years

Sex

All

Key exclusion criteria

1. Treated for ear infection or received antibiotics for any other disease in the previous 2 weeks
2. Other ear problems, e.g. pre-existing ear disease or anatomical abnormalities
3. Foreign body or ear wax that is not able to be removed
4. Known allergy to study drugs

Date of first enrolment

01/02/2009

Date of final enrolment

01/02/2010

Locations

Countries of recruitment

United Kingdom

England

Kenya

Study participating centre

Liverpool School of Tropical Medicine
Liverpool
United Kingdom
L3 5QA

Sponsor information

Organisation

Liverpool School of Tropical Medicine (UK)

ROR

<https://ror.org/03svjbs84>

Funder(s)

Funder type

Charity

Funder Name

Thrasher Research Fund (USA)

Alternative Name(s)

The Thrasher Research Fund, Thrasher Research, TRF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary